Genetic and phenotypic characterisation of HIV‐associated aggressive B‐cell non‐Hodgkin lymphomas, which do not occur specifically in this population: diagnostic and prognostic implications. Issue 6 (4th October 2022)

• Record Type: Journal Article
• Authors: Baptista, Maria Joao; Tapia, Gustavo; Muñoz‐Marmol, Ana‐María; Muncunill, Josep; Garcia, Olga; Montoto, Silvia; Gribben, John G; Calaminici, Maria; Martinez, Antonio; Veloza, Luis; Martínez‐Trillos, Alejandra; Aldamiz, Teresa; Menarguez, Javier; Terol, María‐José; Ferrandez, Antonio; Alcoceba, Miguel; Briones, Javier; González‐Barca, Eva; Climent, Fina; Muntañola, Ana; Moraleda, José‐María; Provencio, Mariano; Abrisqueta, Pau; Abella, Eugenia; Colomo, Lluis; García‐Ballesteros, Carlos; Garcia‐Caro, Montserrat; Sancho, Juan‐Manuel; Ribera, Josep‐Maria; Mate, José‐Luis; Navarro, José‐Tomas;
• Is Part Of: Histopathology. Volume 81:Issue 6(2022)
• Page Start: 826
• Page End: 840
• Publication Date: 2022-10-04
• Subjects: genetics -- phenotype -- HIV -- lymphoma; Histology, Pathological -- Periodicals; 611.018
• DOI: 10.1111/his.14798
• Languages: English
• ISSNs: 0309-0167

Abstract

Abstract : The frequency of aggressive subtypes of B‐cell non‐Hodgkin lymphoma (B‐NHL), such as high‐grade B‐cell lymphomas (HGBL) with MYC and BCL2 and/or BCL6 rearrangement (HGBL‐DH/TH) or Burkitt‐like lymphoma (BL) with 11q aberration, is not well known in the HIV setting. We aimed to characterise HIV‐associated aggressive B‐NHL according to the 2017 WHO criteria, and to identify genotypic and phenotypic features with prognostic impact. Seventy‐five HIV‐associated aggressive B‐NHL were studied by immunohistochemistry (CD10, BCL2, BCL6, MUM1, MYC, and CD30), EBV‐encoded RNAs (EBERs), and fluorescence in situ hybridisation (FISH) to evaluate the status of the MYC, BCL2, and BCL6 genes and chromosome 11q. The 2017 WHO classification criteria and the Hans algorithm, for the cell‐of‐origin classification of diffuse large B‐cell lymphomas (DLBCL), were applied. In DLBCL cases, the frequencies of MYC and BCL6 rearrangements (14.9 and 27.7%, respectively) were similar to those described in HIV‐negative patients, but BCL2 rearrangements were infrequent (4.3%). MYC expression was identified in 23.4% of DLBCL cases, and coexpression of MYC and BCL2 in 13.0%, which was associated with a worse prognosis. As for BL cases, the expression of MUM1 (30.4%) conferred a worse prognosis. Finally, the prevalence of HGBL‐DH/TH and BL‐like with 11q aberration are reported in the HIV setting. The phenotypic and genotypic characteristics of HIV‐associated aggressive B‐NHL are similar to those of the general population, except for the low frequency of BCL2 rearrangements in DLBCL. MYC and BCL2 coexpression in DLBCL, and MUM‐1 expression in BL, have a negative prognostic impact on HIV‐infected individuals. Abstract :